BeOne Medicines Ltd
204 hedge funds and large institutions have $8.11B invested in BeOne Medicines Ltd in 2023 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 53 increasing their positions, 74 reducing their positions, and 30 closing their positions.
27% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 30
1% more funds holding
Funds holding: 201 → 204 (+3)
5% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $14.1M
0.18% less ownership
Funds ownership: 3.78% → 3.6% (-0.18%)
4% less capital invested
Capital invested by funds: $8.46B → $8.11B (-$348M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
28% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 74
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$51.6M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$39.8M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$28.7M |
| 4 |
Goldman Sachs
New York
|
+$24.7M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$12.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$199M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$183M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$114M |
| 4 |
Canada Life
Winnipeg,
Manitoba, Canada
|
-$53.9M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.98M |
ONC Hedge Fund Activity: Q4 2023 in Review
204 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines Ltd (ONC) for Q4 2023, worth a combined $8.11B — down 4.1% from $8.46B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new ONC positions and 30 closed out — a net gain of 8 holders — while 53 added to existing stakes and 74 trimmed.
The largest buyer was Capital International Investors, adding an estimated $51.6M. The largest seller was Baker Bros. Advisors, cutting an estimated $199M.
- 204 institutional investors held BeOne Medicines Ltd (ONC) as of Q4 2023, up from 201 in Q3 2023.
- Funds reported $8.11B of BeOne Medicines Ltd stock for Q4 2023, down 4.1% quarter-over-quarter.
- 38 funds opened new BeOne Medicines Ltd positions in Q4 2023 and 30 closed out, a net change of +8 holders.
- The largest BeOne Medicines Ltd buyer in Q4 2023 was Capital International Investors, an estimated $51.6M added.
- The largest BeOne Medicines Ltd seller in Q4 2023 was Baker Bros. Advisors, an estimated $199M sold.
Based on aggregated 13F filings for Q4 2023.